6 news items
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
ABBV
CYTO
ONCY
24 May 24
, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers." Altamira Therapeutics Ltd
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
ABBV
17 May 24
the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
ABBV
17 May 24
of IBD. Recognizing that every patient is different, AbbVie has taken bold steps to help shape the IBD landscape, building a diverse portfolio
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
ABBV
13 May 24
are optimized for safety, efficacy, and patient access. Gilgamesh is advancing a diverse portfolio of programs, including two lead clinical programs
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
ABBV
ATNM
AZN
22 Apr 24
medications. Johnson & Johnson's (NYSE:JNJ) diverse portfolio, including
z1pnt
ABBV
22 Mar 24
(NYSE:ABBV), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings
- Prev
- 1
- Next